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(57) ABSTRACT 
A method of making a hyperbranched amphiphilic polyester 
compound includes drying under vacuum a mixture of 2-( 4-
hydroxybutyl)-malonic acid and p-toluene sulphonic acid as 
catalyst. The vacuum is then released with a dry inert gas after 
drying. The dried mixture is heated under the inert gas at a 
temperature sufficient for polymerization. The inert gas is 
evacuated while continuing to heat the mixture. The formed 
polymer is then dissolved in dimethylformamide and precipi-
tated out by adding methanol. Modifications of the method 
yield nanoparticles of polyesters having properties suited for 
coencapsulating fluorescent dyes together with therapeutic 
drugs, resulting in theranostic nanoparticles, that is, nanopar-
ticles useful in both therapeutic treatments and diagnostic 
methods. 
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SYNTHESIS OF HYPERBRANCHED 
AMPHIPHILIC POLYESTER AND 
THERANOSTIC NANOPARTICLES THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This is a division of application Ser. No. 12/417,017 filed 
Apr. 2, 2009, entitled "Synthesis of Hyperbranched 
Amphiphilic Polyester and Theranostic Particles Thereof," 10 
which claims the benefit of provisional application Ser. No. 
61/041,624 filed on Apr. 2, 2008. Both of these applications 
are incorporated herein by reference in their entireties. 
2 
ment, where novel targeted multifunctional polymeric nano-
particles can be developed to obtained spatiotemporal infor-
mation about disease stage and progress of a therapeutic 
regime.12-14 Hence, there has been substantial interest in 
developing smart therapeutic and selective polymeric 
vehicles fortargeted treatment of various diseases, preventing 
toxicity to healthy tissues. 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides methods for maing hyperbranched 
amphiphilic polyester compounds. These polyesters may be 
used to generate nanoparticles having one or more hydropho-
STATEMENT OF GOVERNMENT RIGHTS 
This invention was made with government support under 
CAI 01781 awarded by the National Institutes of Health. The 
government has certain rights in the invention. 
15 bic pockets and a hydrophilic outer surface. The polymeric 
nanoparticles (PNPs) may be used as carriers for a hydropho-
bic near-infrared fluorescent dye and/or a therapeutic drug. 
The PNPs are biodegradable and, having been modified with 
appropriate chemical groups along their outer surface, are 
FIELD OF THE INVENTION 
The present invention relates to the field of nanotechnology 
and, more particularly, to nanoparticles useful as carriers of 
fluorescent dyes for diagnostic purposes and therapeutic 
drugs for treatment of disease; these dual-purpose particles 
are also known as "theranostic nanoparticles." 
20 readily taken into cells, thus providing an ideal vehicle for 
delivery of therapeutic drugs. Since the PNPs may carry both 
a fluorescent dye and a therapeutic drug, they can be tracked 
optically via the dye and simultaneously deliver the drug to 
predetermined cells. The capability of having both a thera-
25 peutic modality and a diagnostic modality may be identified 
as "theranostic." 
BACKGROUND OF THE INVENTION 
A method of the present invention includes making a 
hyperbranched amphiphilic polyester compound. The 
method includes drying under vacuum a mixture of 2-( 4-
Polymer science has traditionally focused on linear poly-
mers or cross-linked linear polymers, resulting in a wide 
variety of materials implemented in most facets of daily life. 
Recent progress in polymer sciences has resulted in the devel-
opment of dendrimersl and most recently hyperbranched 
polymers2-4 consisting of branched structures with high 
numbers of reactive groups in their periphery. The syntheses 
30 hydroxybutyl)-malonic acid and p-toluene sulphonic acid as 
catalyst. Then, releasing the vacuum with a dry inert gas after 
drying. The method continues by heating the dried mixture 
under the inert gas at a temperature sufficient for polymeriza-
tion. The method proceeds by evacuating the inert gas while 
35 continuing to heat the mixture, then dissolving the formed 
polymer in dimethylformamide. Finally, the method ends 
after precipitating the dissolved polymer by adding methanol. 
In the method, drying may comprise a mixture of 2-( 4-
hydroxybutyl)-malonic acid and p-toluene sulphonic acid in 
40 approximately a 100:1 molar ratio. Also, drying under 
vacuum preferably comprises a high vacuum and the inert gas 
is argon gas. The heating is preferably at a temperature of 
approximately 150° C., which promotes polymerization. The 
heating may continue for approximately two hours. Evacuat-
of these multifunctional dendritic (branched) polymers hold 
great promise for targeted delivery of drugs, therapeutics, 
diagnostics and imaging. The perfectly branched structures 
called dendrimers are constructed by an iterative and complex 
reaction sequence involving protection-deprotection steps 
whereas hyperbranched polymers, the less perfect structures, 
are made by one step polymerization reaction. Recent 
advances in nonviral drug delivery and cancer chemotherapy 
have revealed biocompatible branched polymers like poly-
ethyleneimine (PEI) and starburst PAMAM as effective drug 
delivery systems, which can mimic naturally occurring bio-
logical transport systems such as lipoproteins and viruses.5 
Unlike linear polymers which are produced from divalent AB 50 
type monomers, dendritic macromolecules are produced 
from polyvalent ABn monomers (n;;,:2), giving rise to its 
branching and multiple-end structures.6-8 Dendritic poly-
mers have gained large interest in recent years because of 
their highly branched structures facilitating effective encap- 55 
sulation of guest molecules and having many attractive fea-
tures such as improved solubility, reactivity, structure archi-
tecture, biocompatibility, low viscosity and low crystallinity 
compared to those of linear polymers of same molecular 
weight.9 Therefore, the creation of new and highly branched 60 
polymeric nano structures with multifunctional capabilities is 
central to the development of novel materials with applica-
tions in various fields ranging from drug delivery, immunoas-
says, microelectrons, coating and nanocomposites.10,11 
Polymeric nanoparticles and nanocomposites with dual fluo- 65 
rescent, magnetic and therapeutic properties will have a huge 
impact in medicine, particularly in cancer diagnosis and treat-
45 ing is most preferably conducted slowly at approximately 0.2 
mm/Hg for about one hour while maintaining the polymer-
ization temperature. After polymerization, the method may 
further comprise purifying the polymer by separating the 
precipitate, washing it with methanol and drying it in a 
vacuum. 
The described method may be modified to make aminated 
PNPs. This is accomplished by dissolving the precipitated 
polymer in anhydrous dimethylformamide (DMF), adding 
1,1'-carbonyldiimidazole drop-wise to form a reaction mix-
ture and incubating the reaction mixture at room temperature 
for approximately one to two hours. This method continues 
by adding ethylenediamine in anhydrous DMF drop-wise and 
continue incubation of the reaction mixture at room tempera-
ture for approximately 24 hours, then precitipating the reac-
tion mixture in methanol, separating the precipitate and dry-
ing in a vacuum to obtain a purified hyperbranched polyester 
amme. 
Yet another modification of the described method is useful 
for making propargylated PNPs. This modification includes 
dissolving the precipitated polymer in anhydrous dimethyl-
formamide (DMF), adding 1,1'-carbonyldiimidazole drop-
wise to form a reaction mixture, incubating the reaction mix-
US 9,095,611 Bl 
3 4 
ture at room temperature for approximately one to two hours, 
then adding propargyl chloride in anhydrous DMF drop-wise 
and continue incubation of the reaction mixture at room tem-
perature for approximately 24 hours. Lastly, the method calls 
for precitipating the reaction mixture in methanol, separating 5 
the precipitate and drying in a vacuum to obtain a purified 
hyperbranched propargylated polyester amine. 
Included in the invention is a polymeric nanoparticle com-
prising the polymer HBPE-PA(7) and a hydrophobic near-
infrared fluorescent dye encapsulated therein. In this poly-
meric nanoparticle the dye may be selected from the group 
consisting of DiI, DiR, and DiD, and there may also be a 
therapeutic drug coencapsulated with said fluorescent dye. 
The therapeutic drug preferably comprises an anti-cancer 
drug, for example, azidothymidine or 25, wherein the anti-
cancer comprises paclitaxel. 
Having described the method and its two modifications, the 
polymers generated thereby represent novel molecules useful 
at least for making the PNPs of the invention. Accordingly, 10 
the invention includes a polymer comprising the repeating 
unit HBPE (5). 
Those skilled in the art will recognize that while certain 
hydrophobic near-infrared fluorescent dyes have been given 
as examples, other dyes having similar properties would also 
be useful in the invention. The same can be expected to hold 
for therapeutic drugs other than the ones given here as 
examples; as long as the drug exhibits sufficient hydropho-
bicity to nest in the hydrophobic pocket formed by the poly-
(5) 15 
0 
HO 
HO 
HBPE 
The invention additionally includes a polymeric nanopar-
ticle comprising the polymer HBPE(5), the nanoparticle also 
having a hydrophobic near-infrared fluorescent dye encapsu-
lated therein. The dye may be selected from the group con-
sisting of DiI, DiR, and DiD. Additionally, this PNP may 
include a therapeutic drug coencapsulated with said fluores-
cent dye, and particularly, an anti-cancer drug such as azidot-
hymidine. 
Another polymer included in the invention is one compris-
ing the repeating unit HBPE-EDA (6). 
(6) 
0 
H1N~HN 
ot H1N~N 
H 
0 
HBPE-EDA 
Moreover, the invention further includes a polymeric nano-
particle comprising the polymer HBPE-EDA( 6) and a hydro-
phobic near-infrared fluorescent dye encapsulated therein. As 
noted above, the dye may be selected from the group consist-
ing of DiI, DiR, and DiD, and the PNP may also include a 
therapeutic drug coencapsulated with said fluorescent dye. 
The other modification of the presently disclosed method is 
useful for making a polymer comprising the repeating unit 
HBPE-PA(7), as set forth below. 
(7) 
0 
~HN 
ot ~N 
H 
0 
HBPE-PA 
mer in the nanoparticle, the drug should be of use in the 
invention. These dyes and drugs as known to the skilled by 
their properties are, therefore, intended to be included within 
20 the scope of the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The patent or application file contains at least one drawing 
25 executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
30 apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
35 
40 
45 
FIG. 1 illustrates, according to a method of the invention, 
the facile synthesis of amphiphilic hyperbranched polyester 
(HBPE, 5) and corresponding polyester-amine (HBPEA, 6) 
polymer, which are highly branched, globular, and biode-
gradable in nature; the polymeric backbone of HBPE was 
synthesized by melt polymerization of the monomer 4, which 
can be easily made from commercially available diethylma-
lonate 1 and bromobutyl acetate (2) in two simple steps, hence 
the synthesis of 5 is cost-effective; the corresponding ami-
nated polymer can be synthesized via conjugation of ethyl-
enediamine using 1,1'-carbonyldiimidazile (CDI) coupling; 
the resulting amphiphilic and dendritic polymers (5 and 6) 
contain inner hydrophobic domain (aliphatic chains), sur-
rounded by a hydrophilic outer shell (carboxylic or amine 
groups), which after self assembly in water result in a stable 
nanoparticle suspension which can encapsulate hydrophobic 
50 dyes and drugs; 
FIG. 2 shows a schematic representation of the structure of 
dendritic polyester (HBPE 5) and corresponding formation of 
polymeric nanoparticles via solvent diffusion method; using 
this method, a series of hydrophobic drugs and dyes can be 
55 encapsulated in one pot; these polymeric nanoparticles are 
highly dispersed in water and stable in a wide range of buff-
ered solutions under physiological conditions; both click 
chemistry, carbodiimide chemistry and other conjugation 
chemistries can be used for the functionalization of these 
polymeric nanoparticles with small molecule like antibodies, 
proteins, oligonucleotides and other targeting agents to gen-
erate a nanoparticle-ligand library; 
60 
65 
FIG. 3 presents an overall schematic representation of the 
preparation of functional polymers and polymeric nanopar-
ticles (PNPs); polymer 5 was synthesized following the melt 
polymerization technique; PNPs were synthesized using the 
solvent diffusion method and were stable in water and other 
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particles is bright and is not accompanied by any significant 
quenching upon encapsulation of photo bleaching upon pro-
longed imaging; 
FIG. 12 shows the hydrodynamic diameters of the nano-
particles as measured by dynamic light scattering (DLS) 
instrument; measurement data shows the average hydrody-
namic diameter of the particles are ranging between approxi-
mately 90±20 nm; 
FIG. 13 presents Scanning Electron Microscope (SEM) 
aqueous buffer solutions; carbodiimide chemistry has been 
followed for the synthesis of functional polymers (6 and 7) 
using 1,1'-carbonyldiimidazole (CDI), as a water insoluble 
carbodiimide. Near IR dyes (DiI, DiD and DiR), paclitaxel 
and AzT encapsulated PNPs were prepared in water from the 5 
water insoluble functional polymers using the solvent diffu-
sion method. Click chemistry and carbodiimide chemistry 
has been used for the synthesis of a library of functional 
PNPs; insets show the structures ofNIR dyes, Paclitaxel and 
AzT; 10 images of the polymeric nanoparticles showing an average 
diameter ranging from 115±25 nm, in accordance with the 
DLS data shown in FIG. 12; remarkably, the black rectangu-
lar box in the image indicates that the nanoparticles are 
FIG. 4 is a representation of the synthesis of azide-func-
tionalized folic acid (13) from chloropropylamine and Cul-
catalyzed "click" chemistry for the preparation of folate-
functionalized PNPs (lla-e); 
FIG. 5 shows 1HNMR spectrumoftheAB2 monomer(3); 15 
the characteristic triplet for the single acidic proton (f) was 
observed at 3.34 ppm; 
spherical in shape, as expected; 
FIG. 14 depicts FT-IR spectra of the final monomer 4 
(Acid), HBPE 5 (Polymer) and the dye encapsulating PNPs 
Sa, demonstrating presence of dye within the PNPs; the pres-
ence of a FT-IR band at 172S cm- 1 for the ester group indi-
cates the formation of the hyperbranched polyester from the 
FIG. 6 depicts a 13C NMR spectrum oftheAB2 monomer 
(3); all peaks are assigned to the corresponding carbons, 
which confirms the presence of the expected compound; 
FIG. 7 shows 1 H and 13C NMR spectra of the final AB2 
monomer (4) using CDC13 as a solvent; absence of the ethyl 
ester protons and acetyl group in the NMR spectra confirms 
the hydrolysis of compound 3 and the formation of compound 
20 monomer (band at 1710 cm-1 for aliphatic carboxylic acid 
group); the band at 1675 cm- 1 is attributed to a conjugated 
alkene group, confirming the encapsulation of the dye inside 
a hydrophobic cavity of the PNPs; 
4; all peaks are assigned to the corresponding protons and 25 
carbons, which confirm the presence of the expected product; 
FIG. 8 shows 1H and 13C NMR spectra of amphiphilic 
hyperbranched polymer (5), confirming the preparation of 
high molecular weight polymer; the broadening of the sharp 
peaks in 1 H NMR spectrum of the monomers also indicates 30 
the formation of polymer having a large number of chemi-
cally equivalent protons with same ll value; 
FIG. 9 provides GPC traces of polyester 5, polymerized at 
150° C. at atmospheric pressure and under high vacuum; a) 
before applying vacuum, showing the presence of low 35 
molecular weight polymers and oligomers; b) high molecular 
weight polymer was formed after applying vacuum; for a 
comparative study between the average molecular weight 
(Mw) and the polymerization time at 150° C., the samples 
were taken from the reaction mixture periodically and ana- 40 
lyzed by GPC; with increasing time there was an increase in 
the molecular weight, whereas a dramatic increase in the 
polymer's molecular weight was observed when high 
vacuum was applied; moreover, when the evacuation was 
continued for more than 2 h, the resulting polymers were 45 
found to be insoluble in all the solvents; the average molecu-
lar weight of polymer (5) was Mw=42,000, PD=l.6; 
FIG. 10 is a TGA thermogram trace of polyester 5 at a 
heating rate of 10° C./min in air; the thermogram obtained is 
typical of an aliphatic hyperbranched biopolymer; the hyper- 50 
branched polymer exhibits a moderate thermal stability; ther-
mal decomposition of the polymer was initiated at -210° C.; 
at 225° C., the polymer has only lost about 2.5% ofits weight, 
mainly due to evaporation of the volatile compounds (such as 
H20, CHC13 and DMF), before the induction of its thermal 55 
degradation; approximately a 10% weight loss occurred at 
250° C.; 
FIG. 11 shows inA) the chemical structure ofDiD, DiI and 
DiR; these dyes are water insoluble in nature and are prima-
rily used to visualize cell membranes; and in B) a photo- 60 
graphic image showing an aqueous (PBS) suspension of 
HBPE nanoparticles encapsulating the corresponding dyes 
(Sa-c ); similarly, one can encapsulate a hydrophobic drug or 
a combination of drug and dye; highly dispersed dyes/drugs 
encapsulated polymeric nanoparticles are stable in wide 65 
range of solvents under physiological conditions. The fluo-
rescence of the resulting dye-encapsulated polymeric nano-
FIG. 15 are UV/Vis spectra of the dye (DiI, DiD, DiR)-
encapsulating PNPs (Sa-c ), showing the presence of the NIR 
dyes with absorption maxima at 552, 650 and 755 nm, respec-
tively; 
FIG. 16 shows the characteristic fluorescence emission 
spectra of dye encapsulating polymeric nanoparticles (Sa-c) 
in DI water; the fluorescence intensity maxima of these nano-
particle solutions at 570 nm, 675 nm and 7SO nm indicate the 
presence ofNIR dyes DiI, DiD and DiR, respectively, in the 
hydrophobic domain of the polymeric nanoparticles; no 
changes in fluorescence intensity or quenching of the dyes 
was observed upon encapsulation and subsequent storage of 
the nanoparticles at 4 ° C. for months, demonstrating the high 
fluorescence stability of these dye encapsulated polymeric 
nanoparticles; note the multiple imaging capability using 3 
different wavelengths; 
FIG. 17 are UV/Vis spectra of the DiI dye encapsulating 
PNPs (Sa) and the dye alone; a blue shift (by 10 nm) was 
observed in the UV/Vis absorption maxima in the case ofDiI 
encapsulating PNPs, which confirmed the presence of the dye 
within the hydrophobic domain of the PNPs; 
FIG. 18 depicts the blue shift (23 nm) in the fluorescence 
emission of DiI encapsulating HBPE nanoparticles (Sa) as 
compared to free dye; this is due to both van-der Walls (hydro-
phobic) and electronic interactions of the dye with the poly-
meric cavity, confirming the presence of dye inside the poly-
mer cavity; 
FIG. 19 shows a photo-stability study of the DiI encapsu-
lating PNPs (Sa) and DiI alone in solution in the presence of 
UV light, demonstrating the stability of the dye when encap-
sulated inside the polymeric cavity compared to the free dye; 
FIG. 20 shows the electrokinetic potential (zeta potential) 
of the synthesized polymeric nanoparticles; the zeta potential 
of the non-aminated polymeric nanoparticles is negative (A, 
s=-54.5 mV), as expected, due to the presence of surface 
carboxylic acid groups; not surprisingly, the zeta potential of 
the aminated polymeric nanoparticles is positive (B, s= 10.33 
mV), where the low positive value indicates the partial ami-
nation of the nanoparticles with the presence ofless number 
of free carboxylic groups than amine groups at the surface; 
FIG. 21 presents cell internalization studies using Xeno-
gen's IVIS 50; in these experiments either carboxylated 
(negative, Sb) or aminated (positive, 9b) nanoparticles were 
incubated with cells from the A549 lung cancer cell line; in 
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these representative studies, near infrared DiR encapsulated 
nanoparticles were used, although similar results were 
observed with DiD and DiI; as expected, internalization was 
observed only when the positively charged aminated DiR 
nanoparticles were used, as judged by the near infrared fluo- 5 
rescence coming from the cell pellets on FIG. 21B; note that 
when carboxylated nanoparticles are used (FIG. 21A), the 
fluorescence remains in the supernatant; these results dem-
onstrate that cationic nanoparticles are a better candidate for 
the cell internalization studies and for cell tracking studies. In 10 
addition, it shows the capability of imaging in the near infra-
red; 
FIG. 22 is a UVNis spectrum of the folate-clicked, DiI-
encapsulating PNPs 1 la, showing the presence of both the 
encapsulated dye (553 nm) and surface clicked with folate 15 
(354 nm); similar results were obtained for the paclitaxel- and 
Dil-encapsulating PNPs 1 ld, prepared for targeted cancer 
therapy; 
FIG. 23 shows an UVNis spectrum of the folate-clicked, 
DiR-encapsulating PNPs 11 b, showing the presence of both 20 
the encapsulated DiR (755 nm) and surface clicked with 
folate (355 nm); 
FIG. 24 shows bar graphs acknowledging the potential 
biomedical applications of the synthesized PNPs; we evalu-
ated their cytotoxicity, through the MTT assay; first, we 25 
examined the potential in vitro differential cytotoxicity of 
carboxylated, aminated, and folate-decorated DiI-containing 
PNPs, using a lung carcinoma (A549) cell line; results indi-
cated that the carboxylated and folate-conjugated PNPs 
exhibited nominal cellular cytotoxicity (less than 4% com- 30 
pared to the control), whereas the aminated PNPs induced cell 
death to approximately 10% of the cell population (FIG. 24a); 
indeed, the folate-decorated DiI and paclitaxel co-encapsu-
lating PNPs (1 ld) induced a significant reduction in cell 
viability, as more than 50% of the cell population underwent 35 
cell death (FIG. 24b); furthermore, as most lung carcinomas 
exhibit aberrant telomerase activity, leading to cell immortal-
ity, we encapsulated the reverse transcriptase inhibitor AzT in 
PNPs (lie); we found that folate-decorated DiI and AzT 
co-encapsulating PNPs induced significant cell death, as pre- 40 
viously reported in literature via inhibition of telomerase 
activity (FIG. 2b ); overall, these data suggest that the induc-
tion of cell death is mainly mediated by either paclitaxel or 
AzT, and not by the fluorophores; control cells were treated 
with lxPBS; average values of four measurements are 45 
depicted±standard error; 
FIG. 25 shows a confocal laser-scanning microscopic 
image of A549 lung cancer cells incubated with DiI dye-
encapsulated carboxylated polymeric nanoparticles (Sa); dye 
encapsulated nanoparticles are incubated with the cells for 6 50 
h; result shows no internalization of the nanoparticles into the 
cytoplasm, which demonstrates that the anionic (carboxylic 
groups at surface) polymeric nanoparticles are not the appro-
priate candidate for cell internalizations; instead, only cell 
membrane stained with the dye (outer red lines); the nucleus 55 
stained with DAPI (blue color); 
FIG. 26 shows a confocal laser-scanning microscopic 
image of A549 lung cancer cells incubated with DiI dye 
encapsulated aminated polymeric nanoparticles (9a); inter-
nalization of the nanoparticles into the cell cytoplasm was 60 
observed, which demonstrates that the cationic (amine groups 
at surface) polymeric nanoparticles are the appropriate can-
didate for cell internalizations; the nucleus stained with DAPI 
(blue color); 
FIG. 27 depicts a confocal laser-scanning microscopic 65 
image of A549 lung cancer cells incubated with DiI dye 
encapsulated folate-immobilized polymeric nanoparticles 
8 
(1 la); the particles were incubated with the cells for 6 h.; 
internalization ofthenanoparticles into the cell was observed, 
demonstrating the presence of folate receptor in the A549 
cancer cells and therefore inducing a folate-receptor medi-
ated internalization; 
FIG. 28 provides a confocal laser-scanning microscopic 
image of A549 lung cancer cells incubated with folate modi-
fied nanoparticles (1 ld) encapsulating both a hydrophobic 
dye (DiI) and a hydrophobic anti-cancer drug (paclitaxel); the 
nanoparticles were incubated with the cells for 6 h. Neither 
the fluorescence intensity of the dye, nor the cytotoxic effects 
of the anti-cancer drug are affected when encapsulated in the 
polymeric nanoparticle; experiments show that paclitaxel-
induced mitotic arrest results in apoptotic cell death of lung 
carcinoma cells (A549); 
FIG. 29 is a confocal laser-scanning microscopic image of 
A549 lung cancer cells incubated with folate modified nano-
particles (Ile) encapsulating both a hydrophobic dye (DiI) 
and a hydrophobic anti-HIV drug (AzT); the nanoparticles 
were incubated with the cells for 6 h; these experiments show 
that AzT-induced mitotic arrest results in apoptotic cell death 
oflung carcinoma cells (A549); 
FIG. 30 provides an assessment of the PNP-cell association 
via flow cytometry, where in a) absence of fluorescence emis-
sion is observed in control mock-treated cells (lxPBS), in b) 
partial association of the dye-loadednon-aminated PNPs (Sa) 
is observed, inc) aminated (9a) and d) folate-decorated (lla) 
nanoparticles interact more profoundly with the cells, as indi-
cated by higher levels of fluorescence emission; and 
FIG. 31 shows drug (paclitaxel) and dye (DiI) release pro-
files of functional PNPs (1 ld) in PBS (pH=7.4) at 37° C.; 
release of paclitaxel (A & B) and DiI (C & D) were observed 
in the presence of an esterase enzyme (A & C) and at pH 4.0 
(B & D); these results indicate thatthe PNPs are degradable in 
the presence of an esterase enzyme and at low pH; a con-
trolled release of drug and dye was observed. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, these illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
Herein, we report the synthesis of novel biodegradable 
hyperbranched polyesters and their use for the synthesis of 
cell-permeable polymeric nanoparticles that encapsulate 
hydrophobic dyes and drugs for dual optical imaging and 
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therapeutic applications. To this date, no one has made bio-
compatible polymeric nanoparticles from diethylmalonate 
based hyperbranched polyester. The design and synthesis of 
diethylmalonate-based AB2 monomer is novel and tuned in 
such a way that the resulting polymer will have three-dimen-
sional molecular architecture with hydrophobic interior and 
hydrophilic segments at the surface (amphiphilic). Selective 
mono-C-alkylation of diethylmalonate using a mild basic 
condition and followed by hydrolysis of the monomer was 
performed to develop a new, water-solubleAB2 monomer for 10 
the synthesis of the hyperbranched polyester. We have 
employed a melt polymerization technique using para-tolu-
enesulfonic acid [p-TSA] as a catalyst to synthesize the novel 
aliphatic and biodegradable hyperbranched polyester. We 
hypothesized that the presence of AB2 branching point and a 15 
hydrophobic butyl chain in the monomer structure could be 
able to generate a highly branched and hydrophobic polymer. 
As a proof-of-principle, the resulting polyester was highly 
branched, amphiphilic, having carboxylic acid groups at the 
surface and obtaining a three dimensional architecture with 20 
hydrophobic cavity. Therefore, compare to the conventional 
linear polymers, our branched polyester is amorphous, 
amphiphilic, soluble, biodegradable, highly surface func-
tional and has cavities for effective encapsulation of guest 
molecules, which suggest its versatility in biomedical appli- 25 
cations. Post-functionalization of this water insoluble poly-
ester has been done using carbodiimide chemistry resulting in 
cationic and clickable hyperbranched polyester. 
A solvent diffusion method has been adopted for the syn-
thesis of polymeric nanoparticles (PNPs) where the hydro- 30 
phobic areas assemble together to minimize contact with the 
aqueous environment, while exposing the hydrophilic seg-
ments containing carboxylic groups at the surface in aqueous 
solution.15•16 This results in the formation of carboxyl func-
tionalized spherical polymeric nanoparticles in water con- 35 
taining inner hydrophobic domains that can encapsulate 
hydrophobic molecules such as dyes and drugs. 17 Note that, 
this is the first example of development of hyperbranched 
polyester based polymeric nanoparticles using solvent diffu-
sion method. Experimental data showed the effective encap- 40 
sulation of various hydrophobic near infrared (NIR) dyes and 
a therapeutic drug without significant precipitation or reduc-
tion of the fluorescent properties. The fluorescence of the 
resulting PNPs is bright and stable, allowing the imaging of 
cells without significant photo-bleaching. Click chemistry 45 
has been used for the synthesis of folate decorated PNPs for 
the targeted cancer therapy. 18- 2° Finally, we have been able to 
encapsulate either a hydrophobic antitumor drug (Paclitaxel) 
10 
cal diagnostics) polymeric nanoparticles for biomedical 
applications including (a) encapsulated chemotherapeutic 
agents (Taxol® and AzT) for HIV and cancer therapy, (b) 
surface functionality (folic acid ligand) for cancer targeting, 
( c) "click" -chemistry-based conjugation of targeting ligands, 
(d) encapsulated NIR dyes for fluorescent imaging capabili-
ties and (e) thermomechanical applications including lumi-
nescent, conductive, magnetic or radioprotection of the cor-
responding polymeric-metallic nanocomposites. 
Results and Discussion 
Synthesis and Characterization of Biodegradable Hyper-
branched Polymers 
The amphiphilic hyperbranched polyester (HBPE 5) was 
rationally designed for the development oftheranostic PNPs 
(nanoparticles providing both a therapeutic agent and a diag-
nostic modality), by employing strategies of nanoparticle 
formation and drug/dye encapsulation in one process. FIG. 
1-2 shows our synthetic strategy, leading to the formation of 
a novel, water soluble, AB2 monomer 4 which upon polymer-
ization gives rise to the water insoluble, biodegradable poly-
mer 5, capable of encapsulating dyes/drugs for therapeutic 
applications. The melt polymerization technique was fol-
lowed for the polymer synthesis, where we observed that at 
the initial stages of polymerization, oligomers and low 
molecular weight polymers were obtained. However, upon 
applying vacuum, a high molecular weight polymer (Mw=42, 
000, PD=l.6) was formed (FIG. 9). The resulting polyester 
was highly branched, having carboxylic acid groups at the 
surface and obtaining a three dimensional architecture with 
hydrophobic cavity. Hence contrary to conventional linear 
polyesters, our branched polymer is amorphous, amphiphilic, 
soluble, highly surface functional, biodegradable and has a 
cavity for effective encapsulation of guest molecules, which 
suggest its versatility in biomedical applications. Through 
thermal gravimetric analysis (TGA), we determined that the 
polymer exhibits moderate thermal stability (10% weight loss 
at 250° C. in air), which is typical for a biodegradable poly-
mer (FIG. 10). The polymer was further characterized using 
spectroscopic and chromatographic techniques (FIG. 5-8). 
Subsequently, the presence of free carboxylic acid groups at 
the surface prompted the generation of a library of functional 
polymers using carbodiimide chemistry. We used 1,1'-carbo-
nyldiimidazole (CDI), as a water insoluble carbodiimide, and 
eitherethylenediamine orpropargylamine forthe synthesis of 
surface-aminated cationic polymer (HBPE-EDA 6) and 
clickable polymer, respectively (HBPE-PA 9, FIG. 3). Hence, 
the former surface-aminated polymer may be a good candi-
date for non-specific cell internalization, whereas, the later 
one might be a platform for targeted therapy due to the facile 
conjugation of specific cellular receptor ligands, such as folic 
acid, via click chemistry (FIG. 4). 
Polymeric Nanoparticle (PNP) Synthesis and Drug/Dye 
Encapsulation 
In order to prepare functional PNPs, a modified solvent 
diffusion method was used, where the nanoparticle formation 
and guest molecule encapsulation in the hydrophobic cavity 
took place in one-pot. The amphiphilic polymer and hydro-
phobic guests were dissolved in anhydrous dimethylforma-
mide (DMF) and added drop-wise to water under continuous 
stirring, driving both the self-assembly and encapsulation 
processes and resulting in the synthesis of functional PNPs. 
The resulting PNPs were highly stable in aqueous buffered 
or, a nucleoside analog reverse transcriptase inhibitor (AzT) 
for the treatment of HIV and AIDS, along with near infra red 50 
fluorescent dyes (DiI or DiR) into the folate decorated PNPs 
for targeted drug delivery and imaging. We have used human 
lung carcinoma (A549) and normal cardiomyocites (h9c2) 
cell lines throughout all in vitro studies. We have assessed 
MTT assay to determine the cytotoxity of our functional 55 
PNPs. Results showed Taxol® and AzT encapsulated PNPs 
were toxic to the cancerous cell lines, whereas, dye encapsu-
lated polymeric fluorophores were non-toxic. These results 
were corroborated with confocal microscopic studies and 
FACS analysis. The PNPs degradation and controlled drug 60 
and dye release experiments were performed under enzy-
matic and low pH environments. Most importantly, we are 
successful in animal imaging using mice model, in vivo, with 
the NIR dye (DiR and DiD) encapsulated PNPs for animal 
imaging applications. 65 solution for more than a year, without significant reduction in 
the fluorescent emission of the encapsulated dyes and can be 
concentrated without significant precipitation. Therefore, 
Therefore, our present protocol is capable of creating a 
library of multifunctional therenostic (therapeutics and opti-
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near infra red dye (DiI, DiR and DiD) encapsulated PNPs 
(Sa-c and 9a-c) were synthesized from the corresponding 
carboxylated and aminated polymers (HBPE 5 and HBPE-
EDA 6, respectively). Alternatively, the aminated PNPs (9a-
c) can be prepared from the carboxylated PNPs (Sa-c) using 5 
water soluble carbodiimide, EDC, [1-ethyl-3-(3-dimethy-
laminopropyl) carbodiimide hydrochloride] and ethylenedi-
amine (FIG. 3). Amination of these nanoparticles was con-
firmed by an overall surface charge Cs-potential) 
measurement, where a positive surface potential was 10 
obtained in the case of aminated PNPs (FIG. 20). Propargy-
lated PNPs were also synthesized with DiI dye (1 Oa), DiR dye 
(!Ob), DiD (lOc), DiI with the anti-cancer drug paclitaxel 
(lOd) and with AzT (lOe) using the above strategy. These 15 
PNPs (1 Oa-e) are very important synthon for the synthesis of 
a library of functional PNPs via click chemistry. To demon-
strate the applicability of click chemistry in this system, the 
alkyne-azide click was engineered to occur at the interface 
between the propargylated carboxylic acid corona of the 20 
PNPs and the aqueous phase in which the azide-functional-
ized folic acid is dissolved. Therefore, folate-decorated PNPs 
(lla-e) were prepared using this 1,3-dipolar cycloaddition 
reaction, click chemistry, mediating the targeted drug deliv-
ery to cancer cells that overexpress the folate receptor (FIG. 25 
4). 
Polymeric Nanoparticle Characterization 
12 
11). Next, NIR dye and paclitaxel co-encapsulated folate-
clickedPNPs (1 la-e) were characterized by UV/Vis spectros-
copy (FIG. 22-23). 
In Vitro Cytotoxicity 
Having in mind the potential biomedical applications of 
the synthesized PNPs, we evaluated their cytotoxicity, 
through the MTT assay. First, we examined the potential in 
vitro differential cytotoxicity of carboxylated, aminated, and 
folate-decorated Dil-containing PNPs, using a lung carci-
noma (A549) cell line. Results indicated that the carboxylated 
and folate-conjugated PNPs exhibited nominal cellular cyto-
toxicity (less than 4% compared to the control), whereas the 
aminated PNPs induced cell death to approximately 10% of 
the cell population (FIG. 24a). Considering these findings, 
the potential use of these PNPs in imaging and drug delivery 
applications, either in vitro or in vivo, is anticipated. Hence, 
we examined if PNPs can be used for targeted drug delivery, 
by examining the cytotoxic efficacy of PNPs co-encapsulat-
ing DiI and the hydrophobic chemotherapeutic agent pacli-
taxel. Indeed, the folate-decorated DiI and paclitaxel co-en-
capsulating PNPs induced a significant reduction in cell 
viability, as more than 50% of the cell population underwent 
cell death (FIG. 24b ). Furthermore, as most lung carcinomas 
exhibit aberrant telomerase activity, leading to cell immortal-
ity, we encapsulated the reverse transcriptase inhibitor AzT in 
PNPs. We found that folate-decorated DiI andAzT co-encap-
sulating PNPs induced significant cell death, as previously 
reported in literature via inhibition of telomerase activity 
(FIG. 24b). Overall, these data suggest that the induction of 
cell death is mainly mediated by either paclitaxel or AzT, and 
not by the fluorophore. Specifically, the enhanced in vitro 
cytotoxicity of the folate-decorated DiI and paclitaxel co-
encapsulating PNPs inA549 cells hints the successful target-
ing of carcinomas that overexpress the folate receptor on their 
plasma membrane. Furthermore, these results suggest that the 
co-encapsulation of a fluorophore and a therapeutic agent in 
our PNPs can be utilized for cellular targeting, such as in 
cancer or anti-HIV CD4+-specific therapeutic regimes, visu-
alization of the drug's homing and monitoring of tumor 
regression in clinical studies. 
In Vitro Cellular Uptake of PNPs 
To demonstrate the capability of our functional PNPs to be 
internalized by cells and eventually exert specific intracellu-
lar activity, various preparations of PNPs were incubated with 
lung carcinoma cells (A549) for 6 h. Confocal images showed 
there was no internalization of the non-aminated PNPs, but 
only the cell membranes were found to be stained with the red 
DiI dye (outer red lines, FIG. 25). This demonstrates the 
The approximate hydrodynamic diameter of the PNPs was 
determined though Dynamic Light Scattering (DLS), ranging 
from 100±20 nm, which was similar to that of the unmodified 30 
nanoparticles (FIG. 12). Well-formed spherical PNPs were 
observed by scanning electron microscopy (SEM, FIG. 13) 
and the average diameter of these PNPs was 115±25 nm, 
demonstrating a direct correlation with the DLS data. 
Remarkably, the black rectangular box in the SEM image 35 
indicates that the shape of the nanoparticles was spherical as 
expected from the structure of the original polymer HBPE 5. 
The formation of hydrophobic microdomains and the encap-
sulation of NIR dyes inside the PNPs were confirmed by 
fluorescence measurement of free DiI dye and encapsulated 40 
DiI in PNPs (Sa, FIG. 18). In this experiment, DiI dye was 
dissolved in DMF and allowed to evaporate at room tempera-
ture and then dispersed in water. A blue shift (by 23 nm) was 
observed in the fluorescence emission of Dil-encapsulated 
HBPE nanoparticles (570 nm) as compared to the free non- 45 
encapsulated DiI dye (593 nm) in water. This indicated the 
presence of the dye inside the electronic environment of the 
polymer's cavity, confirming the presence of hydrophobic 
microdomains in the PNPs. Similar results were obtained 
from UV /Visible spectroscopy studies, where a blue shift was 
observed for the encapsulated DiI (FIG. 17), further confirm-
ing the entrapment of the dye inside the cavity. Interesting 
results were obtained from Fourier Transform Infra Red (FT-
IR) spectroscopy (FIG. 14), and these corroborated the for-
mation of PNPs encapsulating the DiI dye. The presence of 
the aliphatic alkenes' characteristic band at 1675 cm- 1 indi-
cated the encapsulation of DiI via conjugated double bonds 
inside the nanoparticle cavity. Subsequently, we prepared 
three different dye (DiI, DiR and DiD) containing PNPs (Sa, 
50 proof-of-concept that the anionic (carboxylic groups at sur-
face) PNPs are not appropriate candidates for cell internal-
ization. To further corroborate this concept, we used A549 
cells treated with aminated PNPs encapsulating DiI (9a). 
Contrary to the carboxylated PNPs, there was strong inter-
Sb and Sc, respectively) from the polymer 5 as shown in FIG. 
3 and FIG. 15. Characteristic fluorescence emission spectra 
of the dye-loaded PNPs in PBS buffer are shown in FIG. 16. 
The fluorescence intensity maxima of these nanoparticles 
were at 570, 675 and 7SO nm, indicating the presence of the 
NIR dyes DiI, DiD and DiR, respectively, within the hydro-
phobic domain of the PNPs. These functional fluorophore-
containing PNPs were highly stable in aqueous solution (FIG. 
55 nalization of the cationic surface PNPs (FIG. 26). Notably, 
these PNPs did not affect cellular integrity and nuclear sta-
bility, failing to trigger apoptosis, even after 12 h of incuba-
tion. Hence, these results strongly support the notion that 
cationic (surface amine groups) PNPs are better vehicles for 
60 cell internalization. Subsequently, we performed in vitro cel-
lular uptake studies, utilizing a Xenogen IVIS system. Simi-
lar results to the confocal studies were obtained. Specifically, 
aminated PNPs were found intracellularly, as fluorescent 
emission was recorded from the cell pellet. On the other hand, 
65 there was absence of fluorescence emission from the pellet of 
cells treated with non-aminated PNPs, suggesting lack of 
PNP internalization (FIG. 21, IVIS images). Similar results 
US 9,095,611 Bl 
13 
were obtained from other synthesized PNPs (Sb-c and 9b-c) 
through the IVIS setup, in line with the confocal microscopy 
observations. 
Then, we investigated the targeting potential of our PNPs 
and cellularuptake of the folate-clicked PNPs (11 a), compar- 5 
ing these PNPs with the corresponding carboxylated ones 
(Sa). Confocal microscopy revealed the effective uptake of 
the folate-functionalized PNPs by A549 cells (FIG. 27), in 
contrast to the carboxylated ones (FIG. 25). The enhanced 
cellular uptake of the folate-decorated PNPs may be attrib- 10 
uted to folate-receptor mediated internalization. Accordingly, 
through confocal studies, we observed that the efficiency of 
folate-decorated PNPs uptake significantly improved upon 
increasing the incubation time, while no cytotoxic effects 
were observed via the MTT assay. Hence, the enhanced time- 15 
dependent uptake and retention of these PNPs is likely due to 
folate-receptor recycling, which is typical of constitutive 
nutrient receptor endocytic trafficking. Subsequently, to dem-
onstrate the folate-clicked PNPs' (1 la) proof-of-concept 
theranostic capability towards cancer cells, we used DiI and 20 
paclitaxel co-encapsulating PNPs (lOd). Then, the surface 
propargyl groups were clicked with azide-functionalized 
folic acid, in order to achieve targeted drug delivery with 
optical imaging capability for spatiotemporal monitoring. 
Lung carcinoma cells overexpressing the folate receptor were 25 
treated with these PNPs (1 ld). After a 3 h-long incubation, 
confocal microscopic examination revealed cellular internal-
ization and induction of paclitaxel-mediated mitotic arrest 
(FIG. 28), in accordance to the literature. This illustrates that 
paclitaxel' s therapeutic efficacy was preserved, despite its 30 
PNP encapsulation. Furthermore, treatment with paclitaxel-
containing PNPs triggered dramatic cellular morphological 
changes after 12 h of incubation, leading to cell death. Fur-
thermore, as most lung carcinomas exhibit aberrant telom-
erase activity, leading to cell immortality, we encapsulated 35 
the reverse transcriptase inhibitor AzT in PNPs. We found that 
folate-decorated DiI and AzT co-encapsulating PNPs 
induced significant cell death, as previously reported in lit-
erature via inhibition oftelomerase activity (FIG. 29). These 
observations strongly support the importance of encapsulat- 40 
ing this potent anti-tumor agent within the polymeric cavity 
and targeting its delivery, in order to prevent damaging non-
transformed cells and healthy tissue. Taken together, these 
findings support the principle that folate-decorated PNPs can 
target and deliver chemotherapeutic agents to folate-receptor- 45 
overexpressing carcinomas, while visualizing the drug's 
homing. Thus by modifying the targeting moiety at the thera-
nostic PNPs' surface, other carcinomas or ailing cells may be 
targeted tailoring the therapeutic regime, while obtaining 
important spatiotemporal information for clinical decision 50 
making. 
Flow Cytometric Assessment of PNPs Uptake 
To corroborate the PNPs cellular uptake ability, a detailed 
flow cytometry analysis was performed with functional PNPs 
(Sa, 9a and 1 la) and A549 cells. Specifically, through flow 55 
cytometry, we determined the Dil-derived cell-associated 
fluorescence emission in a quantifiable fashion. As shown in 
FIG. 30b, limited fluorescence emission was observed from 
cells treated with the carboxylated PNPs (Sa). This indicated 
nominal cell association of these carboxylated PNPs (Sa), 60 
when compared to the control non-treated cells (FIG. 30a) 
where there was lack of fluorescence emission. This is in 
accordance with the data from the confocal and IVIS studies, 
confirming the observation that the anionic surface of the 
nanoparticles interacts with the cell's plasma membrane. 65 
Contrary to this and similar to the confocal microscopic 
observations, cells incubated with aminated PNPs (9a) 
14 
showed three-fold higher fluorescence emission and binding 
activity when compared to the control mock-treated cells, as 
shown in FIG. 30c. Similar to other cationic small molecules 
and peptides, the interaction of the surface-localized positive 
charge of the aminated PNPs with the negatively charged cell 
membrane facilitated the association of the PNPs with the cell 
membrane at the extracellular milieu and the subsequent cel-
lular uptake and retention, as observed through previously 
discussed in vitro studies. Interestingly, upon clicking the 
carboxylated PNPs with folic acid, a higher cell-associated 
fluorescence emission was observed (FIG. 30d). Notably, the 
profound cellular uptake of the folate-decorated PNPs (1 la), 
being comparable to the aminated ones, is attributed to the 
specific folate-receptor-mediated internalization and intrac-
ellular retaining. Overall this indicates that the specific tar-
geting of PNPs through targeting moieties, such as folate, is 
feasible and equally efficient as the non-specific electrostatic-
mediated uptake of cationic entities, rendering targeted PNPs 
useful for potential in vivo applications. 
Drug/Dye Release Study of Functional PNPs 
The therapeutic application of our polymeric nanoparticles 
is influenced by the rate of release of the encapsulated drug 
from the polymeric cavity. To evaluate 1 ld's drug release 
profile, enzymatic ( esterase) and low-pH degradation experi-
ments were performed. Results indicate a fast release of the 
drug (paclitaxel) from the nanoparticle 1 ld upon esterase 
incubation, reaching a plateau within 4 hours (FIG. 31A). A 
similar release profile of the drug was observed at pH 4.0, 
reaching a plateau within 4 .5 hours (FIG. 3 lB). No significant 
release of the drug was observed from nanoparticles incu-
bated in PBS, pH 7.4. These results demonstrate the stability 
of the polymeric nanoparticles during storage (PBS), and 
their cargo release only after cellular uptake via either 
esterase-mediated degradation or in acidified lysosomes. 
Only after folate-receptor-mediated uptake did the PNPs 1 ld 
become cytotoxic upon intracellular release of the therapeutic 
agent. Interestingly, even slower release of the dye was 
observed, both upon esterase incubation and at pH 4.0 (FIGS. 
31C and 31D). However, no release of the dye was observed 
at normal physiological pH (7.4). The observed differential 
release of the drug vs. the dye from PNPs 1 ld may be attrib-
uted to the drug's (paclitaxel) size and hydrophobic nature. 
Experimental Section 
Materials 
Anhydrous DMF, DMSO, 3-( 4,5-Dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT), 1,1'-Carbonyldiimi-
dazole (CDI), N-hydroxysuccinimide (NHS), AZT (azidot-
hymidine), diethylmalonate and other chemicals were 
purchased from Sigma-Aldrich and used without further puri-
fication. Near Infra Red dyes (DiI-D2S2, DiD-D7757, and 
DiR-D12731) and 4', 6-diamidino-2-phenylindole (DAPI-
D1306) were purchased from Invitrogen, whereas the EDC 
(1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydro-
chloride) was obtained from Pierce Biotechnology. The 
folate-receptor-overexpressing human lung carcinoma cell 
line A549 (CCL-1S5) was obtained from ATCC. Dialysis 
membranes were obtained from Spectrum Laboratories. 
Acetonitrile, tetrahydrofuran and other solvents were pur-
chased from Fisher Scientific and used as received, unless 
otherwise stated. 
Instrumentation 
Infrared spectra were recorded on a PerkinElmer Spectrum 
100 FT-IR spectrometer. UV Nis spectra were recorded using 
CARY 300 BiO UV/Vis spectrophotometer. Fluorescence 
spectra were recorded on a NanoLog Horiba jobin Yvon 
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fluorescence spectrophotometer. NMR spectra were recorded 
on a MERCURY 300 MHz spectrometer using the TMS/ 
solvent signal as an internal reference. Gel permeation chro-
matography (GPC) results were obtained using JASCO MD 
2010 Plus instrument with PD 2020 light scattering Precision 5 
Detector. Thermo gravimetric analyses (TGA) were per-
formed on a SETARAM, Mettler TCl 1 instrument with 
sample sizes 10-20 mg. All the experiments were done using 
16 
51.84, 61.27, 63.89, 169.31, 171.11.IR (CHC13): 2982, 1728, 
1463, 1367, 1233, 1151, 1029, and 860 cm-1. 
Synthesis of 2-( 4-hydroxy butyl)-malonic acid ( 4) 
2-(4-acetoxy-butyl)-malonic acid diethyl ester 3 (5.0 g, 
18.25 mmol, see Section S 1 in the Supporting Information for 
the synthesis of compound 3) was taken in a 100 mL round 
bottom flask containing methanol ( 50 mL) and stirred at room 
temperature for 2 min. To this was added NaOH (2.1 g, 54.74 
mmol) in water (7 mL) and stirred at 90° C. for 8 h. The 
reaction mixture was shifted to room temperature and acidi-
fied (pH 2-3) with the drop-wise addition of dilute hydrochlo-
ric acid at room temperature with constant stirring. The mix-
ture was then concentrated by using rotary evaporator and 
applying vacuum. To this was added chloroform ( 50 mL) and 
Argon gas was bubbled through the solution at 60° C. to 
remove excess HCI. The mixture was filtered and the filtrate 
a heating rate of 10° C./min in air. Atomic Force Microscopic 
(AFM) images were obtained from Dimension 3100 Atomic 10 
Force Microscope from Veeco Digital Instruments. Confocal 
images were taken on a Zeiss Axioskop 2 mot plus confocal 
microscope. Flow Cytometry experiments were performed 
using a BD FACS Calibur multipurpose flow cytometer sys-
tem from BD Biosciences. MTT study has been done using 15 
BIO-TEK Synergy HT multi-detection microplate reader. 
Dynamic light scattering (DLS) studies were done using a 
PDDLS/Coo!Batch 40T instrument using Precision Decon-
volve 32 software and SEM images were taken using Jeol 
20 was concentrated. This was then purified by colunm chroma-6400F scanning electron microscope. IVIS experiments were 
done using IVIS 50 imaging system from Xenogen imaging tography using 35% ethyl acetate in petroleum ether as elu-
technologies. Analytical Thin Layer Chromatography (TLC) ent. 
was performed on glass plates coated with silica gel GF 254 Yield: 2.31 g (72% ). 1 H NMR (300 MHz, CDCl3, ll ppm, J 
and are visualized in iodine vapor. Colunm chromatography Hz): 1.41 (m, 2H), 1.59 (m, 2H), 1.91 (q, 2H, 11=7.3,12=7.8), 
wasperformedusingsilicagel(100-200mesh)andtheeluant 25 3.37 (t, lH, J=7.4), 3.64 (t, 2H, J=6.5), 5.54 (bs, lH). 13C 
is mentioned in the procedures below for each case. NMR (75 MHz, CDC13, ll ppm): 23.53, 28.52, 31.75, 52.64, 
Methods 
Synthesis of 4-bromobutyl acetate (2) 30 
62.11, 170.55. IR (CHC13): 3507, 2941, 1710, 1626, 1459, 
1438, 1391, 1198, 1157, 1050, 947, 772, 741, 664 cm-1. 
Synthesis of Hyperbranched Polyester (HBPE) 5 
The monomer 4 and the catalyst p-toluene sulphonic acid 
(100: 1 molar ratio) were taken in a 10 mL round bottom flask 
and dried under high vacuum followed by the release of 
Tetrahydrofuran (12.2 mL, 148.4 mmol) and potassium 
bromide (21.1 g, 176.5 mmol) were added in a 250 mL round 
bottom flask containing 150 mL acetonitrile. The reaction 
mixture was cooled to 0° C., followed by drop-wise addition 
of acetyl chloride (11 mL, 155.1 mmol). Subsequently, the 
mixture was brought to room temperature, where it was con-
tinuously stirred for 3 6 h. The reaction mixture was poured in 
water and extracted with ethyl acetate. The organic layer was 
washed with water, dried over Na2S04 , and concentrated to 
obtain the pure product as a colorless liquid. 
35 vacuum using dry argon gas. Then the flask was slowly heated 
to 150° C. under argon atmosphere using an oil bath and it was 
kept at this temperature for 2 h. The evolution of the byprod-
uct (water vapor) was clearly visible after the sample was 
heated at 150° C. The melt was evacuated at 0.2 mm/Hg for 1 
40 h while maintaining the same polymerization temperature. 
Yield: 24.3 g (85%). bp: >250° C. 1H NMR (300 MHz, 
CDC13, ll ppm, J Hz): 1.79 (m, 2H), 1.92 (m, 2H), 2.03 (s, 3H), 
3.46 (t, 2H, J=7.6), 4.08 (t, 2H, J=6.7). 13C NMR (75 MHz, 
CDC13, ll ppm): 20.87, 27.36, 29.36, 33.03, 63.43, 170.95. IR 45 
(CHC13): 3038, 2926, 1352, 1243, 1052 cm1. 
Synthesis of 2-( 4-Acetoxy-butyl)-malonic acid 
diethyl ester (3) 
The polymer was purified by dissolving in DMF and repre-
cipitating in methanol. This was then centrifuged, washed 
with methanol and dried in a high vacuum pump to get pure 
polymer. 
Yield: 65%. 1 H NMR (300 MHz, DMSO-d6 , ll ppm): 1.25 
(m, 2H), 1.52 (m, 2H), 1.67 (m, 2H), 3.38 (m, lH), 3.58 (m, 
2H), 5.28 (m, lH). 13C NMR (75 MHz, DMSO-d6 , ll ppm): 
23.82, 28.23, 51.85, 52.63, 65.37, 170.45. IR: 2954, 1727, 
1458, 1436, 1343, 1218, 1152, 1054, 943, 858, 743, 694 
50 cm-1. TGA: 10% weight loss at 250° C. 
Compound 3 was prepared by following a previously 
reported method.{Santra, 2004 #6} Briefly, diethyl malonate 
1 (10 g, 62.5 mmol), 4-bromobutyl acetate 2 (15.84 g, 81.3 
mmol) were placed in a round bottom flask containing aceto-
nitrile (120 mL) and stirred for 2 min at room temperature. 55 
Then to this, we added potassium carbonate (34.5 g, 250.1 
mmol) and refluxed for 36 h. Next, the mixture was filtered 
and the filtrate was concentrated to obtain a yellow liquid. 
This was extracted with ethyl acetate, and washed with water. 
The organic layers were combined and dried over Na2S04 , 60 
and purified by colunm chromatography using 4% ethyl 
acetate in petroleum ether as the eluent. 
Yield: 13.02 g (76%). bp: 250° C. 1H NMR (300 MHz, 
CDC13, ll ppm, J Hz): 1.28 (t, 6H, J=7.6), 1.38 (m, 2H), 1.62 
(q, 2H, J=7.2), 1.98 (q, 2H, J=7.7), 2.05 (s, 3H), 3.34 (t, lH, 65 
J=7.7), 4.09 (t, 2H, J=6.6), 4.22 (q, 4H, J=7.2). 13C NMR (75 
MHz, CDC13, ll ppm): 14.06, 20.79, 23.74, 28.25, 28.25, 
Synthesis of Hyperbranched Polyester Amine 
(HBPE-EDA) 6: Carbodiimide Chemisrty 
The polymer 5 (0.1 g, 0.0025 mmol) was dissolved in 
anhydrous DMF (1 mL) using vortex mixture and to this was 
added 1,1'-carbonyldiimidazole CDI (0.041g,0.25 mmol) in 
anhydrous DMF (0.1 mL) drop-wise. The reaction mixture 
was incubated for 2 h at room temperature. To this was then 
added ethylenediamine (0.015 g, 0.25 mmol) in anhydrous 
DMF (0.4 mL) drop-wise and incubated at room temperature 
for 24 h. The resulting reaction mixture was then precipitated 
in methanol, centrifuged and dried in a vacuum pump to get 
pure aminated polymer. 
Yield: 88%. 1 H NMR (300 MHz, DMSO-d6 , ll ppm): 1.27 
(m, 2H), 1.55 (m, 2H), 1.74 (m, 2H), 2.26 (m, 4H), 2.88 (m, 
4H), 3.34 (m, lH), 3.63 (m, 4H), 4.04 (m, 2H). IR: 3245, 
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2940,2864,1725,1659,1534,1435,1240,1159,1062,1021, 
952, 929, 826, 749, 704, 663 cm- 1 . 
18 
flash colunm chromatography using 4% ethyl acetate in 
petrolium ether as an eluant, in order to obtain the pure 
aminopropylazide. 
Synthesis of Clickable Hyperbranched Polyester 
(HBPE-PA) 7: Carbodiimide Chemistry 
Similar procedure has been followed as described for the 
synthesis of polymer 6. Instead of ethylenediamine, propar-
gylamine (0.014 g, 0.25 mmol) was used as the starting mate-
rial. 
Yield: 5.1 g (68%). 1H NMR (300 MHz, CDC13 , ll ppm): 
5 1.26 (bs, 2H), 1.81 (m, 2H), 2.80 (t, 2H), 3.38 (t, 2H). IR 
(CHC13 ): 3307, 2941, 2089, 1663, 1433, 1370, 1259, 1242, 
1075, 1026, 818, 760 cm- 1 . 
10 
Yield: 80%. 1HNMR (500 MHz, DMSO-d6 , llppm): 1.28 
(m, 2H), 1.54 (m, 2H), 1.75 (m, 2H), 2.25 (m, 2H), 3.42 (bs, 
lH), 3.96 (m, 4H), 4.03 (m, 2H). IR: 3121, 2938, 2864, 2698, 
2607, 1725, 1664,1530, 1458,1437, 1388, 1326,1254, 1158, 15 
1094, 1062, 929, 827, 748, 662 cm- 1 . 
Synthesis of Azide-Functionalized Folic Acid 13 
1,1'-carbonyldiimidazole CDI (0.022 g, 0.014 mmol) was 
taken in an Eppendorf Tube® containing folic acid (0.05 g, 
0.011 mmol) in anhydrous DMF (2 mL) and incubated for 2 
hat35° C. To this weaddedaminopropylazide (0.014 g, 0.014 
mmol) in anhydrous DMF (100 µL) and incubated it for 24 h 
at room temperature. The reaction mixture was then cetri-
fuged and washed to remove excess starting materials. 
Finally, we dissolved the azide-functionalized folic acid in 1 
mL of DMF. The presence of a band at 2091 cm- 1 in the IR 
General Procedures for the Synthesis of Functional 
Polymeric Nanoparticles Dye-Encapsulating PNPs 
(8-10): Solvent Diffusion Method 
Different near IR dye (DiI, DiR or DiD) solutions were 
prepared by mixing 5 µL of the dye aliquot (10 µg/µL) in 250 
µL ofDMF. The polymers (5, 6 or 7, 0.025 g) were dissolved 
20 spectrum and a UV absorbance shoulder at 354 nm confirmed 
the formation of azide-functionalized folic acid. 
Yield: 0.05 g (86%). 1H NMR (400 MHz, DMSO-d6 , ll 
ppm): 1.61(m,2H), 1.65 (m, 2H), 1.90 (m, 2H), 2.19 (t, 2H), 
2.78 (t, 2H), 4.18 (q, lH), 4.21(d,2H), 6.62 (d, 2H), 7.59 (d, 
25 2H), 8.58 (s, lH). FT-IR (Neat): 3024, 2097, 1685, 1603, 
1492,1375,1291,1248,1180,1122,1062,950,844,755,696 
in 250 µL of anydrous DMF using a vortex mixturer and 
mixed seperately with different dye solution. The resulting 
polymer-dye mixture in DMF was added drop-wise to deion-
ized water (5 mL) with continuous stirring at room tempera-
ture forming dye encapsulated polymeric nanoparticle. The 
nanoparticle solution was dialyzed (using 6-8 K molecular 30 
weight cut off dialysis bag) three times against deionized 
water and phosphate buffered saline (PBS) solution. 
Paclitaxel (Taxol@) and DiI co-encapsulating 
polymeric nanoparticles 1 Od 
Taxol® (5 µL, 1 mg/mL) andDiI dye (5 µL, 10 µg/µL)were 
taken in an EppendorfTube® containing propargylated poly-
mer (7, 0.025 g) in 500 µL DMF and followed the solvent 
diffusion method as described above. 
AZT and DiI Co-Encapsulating Polymeric 
Nanoparticles lOe 
cm- 1 . 
Synthesis of Folate-Functionalized PNPs 1 la-e: 
Click Chemisrty 
The propargylated polymeric nanoparticles 1 Oa-e (0.025 g, 
6x10-3 mmol) in bicarbonate buffer (pH=8.5) were taken to 
an eppendorf containing catalytic amount of Cul (0.11 µg, 
35 6xl 0-10 mmol) in 250 µL of bicarbonate buffer, vortexed for 
30 seconds. To this was added azide-functionalized folic acid 
(13, 0.003 g, 6x10-2 mmol) in DMSO and the reaction was 
incubated at room temperature for 12 h. The final reaction 
mixture was purified by dialysis using 6-8 K molecular 
40 weight cut off dialysis bag, against deionized water and phos-
phate buffered saline (PBS) solution. The purified functional 
PNPs (lla-e) were stored in refrigerator for further charac-
terization. 
Cell Culture and Cell Viability Studies 
Lung carcinoma cells (A549) were grown in Kaighn's 
modification of Ham's F12 medium (F12K-Cellgro ), supple-
mented with 5% fetal bovine serum (Heat-inactivated FBS-
Cellgro ), L-glutamine, streptomycin, amphotericin B, and 
sodium bicarbonate. The cells were maintained at 37° C., 5% 
AZT (azidothymidine) was dissolved in DMF to a final 45 
concentration of 1 mg/mL. The polymers (5 or 7, 0.025 g) 
were dissolved in 250 µL of DMF using a vortexer. Subse-
quently, AZT (5 µL, 1 mg/mL) andDiI (5 µL, 10 µg/mL)were 
added to the polymer solutions, followed by vortexing. The 
resulting polymer-AZT-Di! mixture in DMF was added drop-
wise to deionized water (5 mL) with continuous stirring at 
room temperature forming DiI and AZT co-encapsulating 
polymeric nanoparticles. The nanoparticle solutions were 
dialyzed (using 6-8 K molecular weight cut off dialysis bag) 
three times against deionized water and phosphate buffered 
saline (PBS) solution. 
50 C02 in a humidified incubator. We used the MTT assay in 
order to assess potential cytotoxic effects upon in vitro 
administration of the drug/dye-encapsulating functional 
HBPE nanoparticles. Specifically, lung carcinoma cells 
(3000 cells/well) were seeded in 96-well plates, and were 
55 incubated with the nanoparticles for 3 hours at 37° C. Then, 
each well was washed three times with lxPBS and treated 
with 20 µl MTT (5 µg/µl, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazo-lium bromide, Sigma-Aldrich) for 2 hours. 
The resulting formazan crystals were dissolved in acidified 
Synthesis ofAminopropylazide 12 
60 isopropanol (0.1 N HCl) and the absorbance was recoded at 
570 nm and 750 nm (background), using a Synergy HT multi-
detection microplate reader (Biotek). These experiments 
were performed in triplicates. 
Chloropropyl amine (7 .0 g, 7 5 .26 mmol) and sodium azide 
(14.23 g, 225.81 mmol)weretakenina lOOmLround bottom 
flask containing 40 mL of distilled water and heated at 80° C. 
for 20 h. The reaction mixture was concentrated via a 
rotavapor using high vacuum, and 2 g of KOH was added to it 
and then extracted by using diethyl ether. Subsequently, the 65 
reaction mixture was dried over anhydrous sodium sulphate 
and concentrated. Then, the mixture was purified through 
Cellular Internalization 
Initially, in vitro uptake and internalization of the PNPs 
was assessed through fluorescence laser-scanning confocal 
microscopy, using a Zeiss LSM 510 confocal microscope. 
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Specifically A549 cells (103 ) were incubated for the stated 
time period with the corresponding PNP preparation in a 
humidified incubator (37° C., 5% C02). Subsequently, the 
cells were thoroughly washed three times with 1 xPBS and 
fixed with a 10% formalin. Nuclear staining with DAPI was 5 
performed as recommended by the supplier. Then, multiple 
confocal images were obtained, achieving a representative 
view of the cell-PNP interaction. Confirmation of the confo-
cal studies was facilitated through FACS and IVIS analyses. 
For FACS, 105 lung carcinoma cells were incubated for 6 10 
hours with the corresponding PNP preparation. Then the cells 
were detached from the culture dish with 0.05% trypsin, and 
the resulting pellet was resuspended in 1 mL culture media. 
The cell suspension underwent flow cytometric analysis, 
using a BD FACSCalibur system, in order to quantify the 15 
cellular uptake of the synthesized PNPs. For the IVIS analy-
sis, 105 lung carcinoma cells were incubated for 6 hours with 
the corresponding PNP preparation, and then the supernatant 
was collected in eppendorf tubes. Subsequently, we thor-
oughly washed the cells with lxPBS and detached them, as 20 
stated above. The resulting pellets were resuspended in 1 ml 
culture media. All EppendorfTubes® were examined simul-
taneously on a Xenogen IVIS sytem, using the following filer 
sets: DsRed (500-550 nm/575-650 nm for Dil), Cy5.5 (615-
665 nm/695-770 nm for DiD) and ICG (710-760 mn/810-875 25 
nm for DiR). All experiments were performed in triplicates. 
In vitro drugldye release: 
The in vitro drug/dye release studies were carried out using 
a dynamic dialysis technique at 37° C. Briefly, 100 µL of 
PNPs (11 d) are incubated with a porcine liver esterase (20 µL) 30 
inside a dialysis bag (MWCO 6000-8000), which is then 
placed in a PBS solution (pH 7.4). The amount of guest (dye 
or drug) molecules released from the nanoparticle into the 
PBS solution was determined at regular time intervals by 
taking 1 mL aliquots from the PBS solution and measuring 35 
the fluorescence intensity at 575 nm for Dil and 372 nm for 
Taxol®®. The concentration of the either dye or drug was 
calculated using a standard calibration curve. The cumulative 
fraction of release versus time was calculated using the fol-
lowing equation: 40 
Cumulative release(% )~[guest]/[guest l<a<alx 100 
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What is claimed is: 
1. A polymer comprising the repeating unit 
(5) 
0 
HO 
HO 
0 
HBPE 
Where [guest], is the amount of guest released at time t, 
[guest ltotaZ is the total guest present in the guest encapsulated 
PNPs. 
2. A polymeric nanoparticle comprising the polymer of 
45 claim 1. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
3. The polymeric nanoparticle of claim 2, further compris-
ing a hydrophobic near-infrared fluorescent dye encapsulated 
therein. 
of limitation. The invention has been described in consider- 50 
4. The polymeric nanoparticle of claim 3, wherein the dye 
is selected from the group consisting of Dil, DiR, DiD, and 
combinations thereof. able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
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5. The polymeric nanoparticle of claim 2, further compris-
ing a therapeutic drug encapsulated therein. 
6. The polymeric nanoparticle of claim 5, further compris-
55 ing a fluorescent dye co-encapsulated with said therapeutic 
drug. 
7. The polymeric nanoparticle of claim 5, wherein the 
therapeutic drug comprises an anti-cancer drug. 
8. The polymeric nanoparticle of claim 5, wherein the 
60 therapeutic drug comprises azidothymidine. 
9. The polymeric nanoparticle of claim 2, wherein the 
polymeric nanoparticle is biodegradable. 
10. The polymeric nanoparticle of claim 2, having one or 
more internal hydrophobic pockets and a hydrophilic outer 
65 surface. 
11. The polymeric nanoparticle of claim 2, having an aver-
age diameter of 115±25 nm. 
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12. The polymeric nanoparticle of claim 2, being spherical 
in shape. 
13. The polymeric nanoparticle of claim 2, having a nega-
tive zeta potential. 
14. An aqueous suspension of the polymeric nanoparticle 5 
of claim 2. 
15. The aqueous suspension of claim 14, further compris-
ing a hydrophobic near-infrared fluorescent dye. 
16. The aqueous suspension of claim 14, further compris-
ing a therapeutic drug. 10 
17. The aqueous suspension of claim 14, further compris-
ing a hydrophobic near-infrared fluorescent dye and a thera-
peutic drug. 
* * * * * 
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